Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Maxis Clinical Sciences: Strategic Management Services

## Sitemaps
[XML Sitemap](https://maxisclinical.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Navigating Gaps in Global RWE Feasibility Criteria: A Regulatory Guide](https://maxisclinical.com/insights/blog/navigating-gaps-in-global-rwe-feasibility-criteria-a-regulatory-guide/): Real-world evidence (RWE) has evolved from a promising concept into a central component of regulatory decision-making1,2. Today, global health authorities rely on RWE to understand how therapies perform in real clinical settings beyond the controlled environments of randomized trials. But here’s the problem: while everyone agrees RWE is valuable, no one can agree on the rules.
- [What Generative AI Means for HEOR: A Practical Taxonomy of Tools and Applications](https://maxisclinical.com/insights/blog/what-generative-ai-means-for-heor-a-practical-taxonomy-of-tools-and-applications/): Sponsors of pharmaceuticals and biotechnology face growing demands to provide evidence faster, more affordably, and more transparently. Systematic reviews, model development, and dossier preparation long have been resource-intensive and scale slow HEOR activities. Generative AI has appeared on the scene not as some eventual development, but as a workable workhorse of faster timelines and greater analytic opportunity1-3. While the concept of using artificial intelligence to enhance human capability dates to the 1950s4, major strides came in the 1990s3 with the emergence of machine learning, improving how systems identify patterns and support decision-making. By the early 2000s, deep learning fueled by neural networks expanded AI’s capabilities into complex domains such as image interpretation and natural language understanding3,5.
- [Pragmatic Clinical Trials: Why the Industry’s Boldest Vision Still Struggles to Deliver](https://maxisclinical.com/insights/blog/pragmatic-clinical-trials-why-the-industrys-boldest-vision-still-struggles-to-deliver/): Pragmatic clinical trials have moved beyond being a new idea, they are now a critical part of how we advance medical research. They mark a meaningful shift toward studies that reflect everyday clinical practice, diverse patient populations, and the realities of care delivery. But adopting this approach isn’t just about being open to change. It takes coordination across teams, well-prepared data systems, and a thoughtful approach to simplifying trial design without compromising on quality. With growing regulatory support and better tools now available, sponsors have a clear opportunity: to lead by example and help make pragmatic trials a more routine part of clinical development. The tools exist. The frameworks are in place. What is needed now is action.
- [Adaptive Protocols in Early Trials: Boosting Success with AI](https://maxisclinical.com/insights/blog/adaptive-protocols-in-early-trials-boosting-success-with-ai/): AI enhances adaptive protocols by:
- [How FSP Models and Strategies Are Evolving to Meet the Changing Needs of Clinical Research](https://maxisclinical.com/insights/blog/how-fsp-models-and-strategies-are-evolving-to-meet-the-changing-needs-of-clinical-research/): At Maxis Clinical Sciences, we understand that every trial is unique. That’s why we offer a range of FSP models, from flexible hybrid teams to fully managed solutions, all designed to fit the specific needs of each sponsor. We also combine our expertise with smart technology—such as data management tools and AI-driven workflow solutions—to help teams work more efficiently and stay ahead of challenges.
- [OMOP CDM Explained: Standardization of Healthcare Data Information](https://maxisclinical.com/insights/blog/omop-cdm-explained-standardization-of-healthcare-data-information/): This is where OMOP CDM comes in. OMOP CDM was developed by medical researchers from around the globe and it provides the framework to bridge the gap between health data and segments. OMOP CDM aids in standardizing every bit of information. The ultimatum is transformed to actionable insights by allowing clinicians and researchers to collaborate compare and organize information.
- [37th Pharmacovigilance UK & EU 2025](https://maxisclinical.com/insights/news-and-events/events/37th-pharmacovigilance-uk-eu-2025/): Join us for an illuminating session where Dr. Kavita Lamror, Partner of RWE & Digital Transformation at Maxis Clinical Sciences, will show you how to enhance patient safety by effectively using real-world healthcare data. Dr. Lamror will demonstrate how combining everyday patient experiences with modern digital tools can strengthen your safety monitoring practices. You'll learn how to bridge traditional pharmacovigilance methods with innovative digital approaches to better protect patient well-being.
- [What Are FSP Models? A Comprehensive Overview for Clinical Trial Sponsors](https://maxisclinical.com/insights/blog/what-are-fsp-models-a-comprehensive-overview-for-clinical-trial-sponsors/): An FSP model is a type of outsourcing arrangement in which a sponsor engages a contract research organization (CRO) or other service provider to deliver specific functional services for a clinical trial. These services can range from data management and biostatistics to clinical monitoring and regulatory affairs. The key characteristics of FSP models include:
- [5 Root Causes of Budget Overages in Clinical Trials: How FSP Models Can Help](https://maxisclinical.com/insights/blog/5-root-causes-of-budget-overages-in-clinical-trials-how-fsp-models-can-help/): The narrative around budget overages in clinical trials is changing. No longer accepted as an unavoidable cost of doing business, these financial challenges are now seen as opportunities for optimization. Through comprehensive understanding of these root causes and strategic deployment of FSP models, sponsors can enhance clinical research productivity, reduce costs, and expedite the development of life-changing therapies faster and more reliably.
- [Maxis Clinical Sciences Publishes A Whitepaper On Opportunities of using Generative AI](https://maxisclinical.com/insights/press-release/maxis-clinical-sciences-publishes-a-whitepaper-on-opportunities-of-using-generative-ai/): Maxis Clinical Sciences (MCS), a trusted brand and management consulting and strategic advisory company for Pharma and Life Sciences companies, has today published a comprehensive whitepaper that discusses the remarkable possibilities of generative artificial intelligence (Generative AI) in various industries.
- [Maxis Clinical Sciences Publishes Whitepaper on Generating Synthetic Medical Data, Revealing Comprehensive Approaches and Applications](https://maxisclinical.com/insights/press-release/maxis-clinical-sciences-publishes-whitepaper-on-generating-synthetic-medical-data/): Maxis Clinical Sciences (MCS), a trusted brand and management consulting and strategic advisory company for Pharma and Life Sciences Innovators, today published a groundbreaking whitepaper focusing on synthetic medical data generation.
- [Integrating Real-World Evidence (RWE) for Accessible Oncology Treatments – Cancer Survivors Month](https://maxisclinical.com/insights/media/corporate/integrating-real-world-evidence-rwe-for-accessible-oncology-treatments-cancer-survivors-month/): Integration of RWE with RCTs can speed-up drug development and bring new therapies to patients faster. This is especially important in oncology, where rapid advancements are required for patients benefit.
- [ISPOR 2024: Key Takeaways, Trends and Insights for HEOR](https://maxisclinical.com/insights/blog/ispor-2024-key-takeaways-trends-and-insights-for-heor/): The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosts an annual conference where experts from around the world share their latest research findings. The ISPOR 2024 conference, held May 5-8, 2024, brought together the brightest minds in HEOR for a stimulating and informative experience. This conference showcased the latest methodological advancements and the progressive role of HEOR in a healthcare landscape that is becoming more complex and data-driven. Experts from Maxis Clinical Sciences actively participated in the discussion, extracting important takeaways and trends that will impact future evidence-based decision-making.
- [Whole Person Health and the role of RWE An interview with Dr Kavita Lamror, Partner, RWE & Digital Transformation, Maxis Clinical Sciences](https://maxisclinical.com/insights/media/corporate/whole-person-health-and-the-role-of-rwe-an-interview-with-dr-kavita-lamror-partner-rwe-digital-transformation-maxis-clinical-sciences/): Dr Kavita LamrorPartner, RWE & Digital Transformation, Maxis Clinical Sciences
- [PharmaSUG 2024](https://maxisclinical.com/insights/news-and-events/events/pharmasug-2024/): Dipika DasDirector - Business Development, Staffing & FSP
- [ISPOR Atlanta 2024](https://maxisclinical.com/insights/news-and-events/events/ispor-atlanta-2024/): Khooshbu SinghDirector - Business Development, RWE and Digital Transformation
- [AI in Clinical Trials: Optimizing Study Design for Better Results](https://maxisclinical.com/insights/blog/ai-in-clinical-trials-optimizing-study-design-for-better-results/): The search for new and better medical treatments is a long and arduous journey. A very important step is the clinical trial, where potential therapies are rigorously tested. With Artificial Intelligence - AI in Clinical Trials, designing and conducting these studies can become more efficient and effective. This could accelerate drug development, bringing life-changing treatments to patients faster.
- [BIO-Europe Spring 2024 Barcelona](https://maxisclinical.com/insights/news-and-events/events/bio-europe-spring-2024-barcelona/): Shibra TupkeAssociate Director - Business Development, RWE and Digital Transformation
- [Maxis Clinical Sciences Launches New Website to Drive Global Engagement and Foster Innovation](https://maxisclinical.com/insights/press-release/maxis-clinical-sciences-launches-new-website-to-drive-global-engagement-and-foster-innovation/): Maxis Clinical Sciences (MCS), a trusted brand and expert management consulting and strategic advisory organization for Pharma and Life Sciences Innovators, is delighted to announce the launch of its new website. This initiative reflects MCS's dedication to global growth and delivering innovative solutions for the industry's evolving demands.
- [Maxis Clinical Sciences Continues Global Expansion with Launch of Newest Office in Pune, India​](https://maxisclinical.com/insights/press-release/maxis-clinical-sciences-continues-global-expansion-with-launch-of-newest-office-in-pune-india/): This press release can be viewed online at: https://www.prlog.org/13007119-maxis-clinical-sciences-continues-global-expansion-with-launch-of-newest-office-in-pune-india.html
- [Top 5 Key Trends in Real-World Evidence to Watch for in 2024](https://maxisclinical.com/insights/blog/top-5-key-trends-in-real-world-evidence-to-watch-for-in-2024/): RWE research is playing an increasingly important role in health care decision-making. Multiple international initiatives, guidelines, and legal frameworks have been released by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) over the years. RWE has already been included in various approval procedures by regulatory authorities, reflecting its actual acceptance and growing importance in evaluating and accelerating new therapies. The FDA and EMA play a pro-active role in exploring gaps and potentials of RWE to guide stakeholders.2,3 The ongoing implementation of RWE in early benefit assessments of newer therapies will potentially speed up approval processes for effective interventions and reduce costs of drug development, which will in turn reduce time-to-market, leading to early patient access. Newer research from non-traditional data sources and various types of digital health technologies (DHTs) will increase in the near future. Initiatives have been kicked off to fund RWE projects, and there is a conscious attempt by the regulators and the industry to involve all stakeholders in the development of future guidelines to increase the trust, credibility, reproducibility, and transparency of RWE studies.
- [SCOPE US Summit 2024](https://maxisclinical.com/insights/news-and-events/events/scope-us-summit-2024/): Khooshbu SinghDirector - Business Development, RWE and Digital Transformation
- [Maxis Clinical Sciences Launches Real-World Evidence Solutions for Patient-Centered Clinical Research & Drug Development](https://maxisclinical.com/insights/press-release/maxis-clinical-sciences-launches-real-world-evidence-solutions-for-patient-centered-clinical-research-drug-development/): Maxis Clinical Sciences, a trusted brand for small to medium-sized pharmaceuticals and life sciences companies worldwide, announced today the launch of its latest offering — Real-World Evidence Solutions.
- [Real-World Evidence and Digital Transformation in Focus: Q&A with Dr. Kavita Lamror](https://maxisclinical.com/insights/blog/real-world-evidence-and-digital-transformation-in-focus-qa-with-dr-kavita-lamror/): In our latest Real World Evidence (RWE) blog, we are privileged to converse with Dr. Kavita Lamror, the newly appointed Partner for RWE and Digital Transformation at Maxis Clinical Sciences (MCS). With a career that spans over 15 years in pharma and healthcare, Dr. Lamror brings a unique blend of clinical expertise and data analytics skills. Her leadership is poised to augment MCS’ capabilities in the RWE domain, aligning well with our organizational objectives and ethos.
- [From Inside Out: How Strategic Talent Mapping Drives Diversity and Equity in Clinical Trials](https://maxisclinical.com/insights/blog/from-inside-out-how-strategic-talent-mapping-drives-diversity-and-equity-in-clinical-trials/): Strategic Talent Mapping helps us build the diverse leadership teams that are essential for ensuring every patient deserves the best possible care, regardless of background. To make sure clinical trials are truly effective, we need leaders who understand the unique needs of all patients. This approach makes research more inclusive and patient-centered.
- [Maxis Clinical Sciences Expands to UK & Europe, Reinforcing Global Clinical R&D Impact](https://maxisclinical.com/insights/press-release/maxis-clinical-sciences-expands-to-uk-europe-reinforcing-global-clinical-rd-impact/): Maxis Clinical Sciences, a leading provider of clinical and digital solutions for the life sciences and healthcare sectors, is excited to announce its expansion into the UK and Europe. This significant milestone enables Maxis Clinical to broaden its reach, augmenting global consulting services and delivering bespoke solutions for clients.
- [5 Proven Strategies for Effective Management of FSP in Clinical Trials](https://maxisclinical.com/insights/blog/5-proven-strategies-for-effective-management-of-fsp-in-clinical-trials/): Clinical trials hold the promise of better treatments, but the process is far from simple. From planning to paperwork to analyzing results, there's a ton to manage. Then there's the 'what if we could get expert help?' moment. That's what FSPs in clinical trials are all about – they bring the skills and experience to make sure those trials succeed.
- [Software As A Medical Device (SaMD): All You Need To Know](https://maxisclinical.com/insights/blog/software-as-a-medical-device-samd-all-you-need-to-know/): Software As A Medical Device (SaMD) has transformed the way healthcare is delivered. With the advancements in technology, SaMD has become more prevalent. This makes the role of SaMD regulations and development even more critical to ensuring the safety and efficacy of these healthcare solutions
- [Integrating Artificial Intelligence in Drug Discovery](https://maxisclinical.com/insights/blog/integrating-artificial-intelligence-in-drug-discovery/): Although artificial intelligence technology is still developing, it has prompted a paradigm shift in clinical research. Machine learning (ML), a data-driven branch of AI that automates analytical model development, allows researchers to complete tasks more accurately and quickly. This, in turn, gives front-line healthcare personnel the power to treat patients effectively.
- [Decentralized Clinical Trials – The Future](https://maxisclinical.com/insights/blog/decentralized-clinical-trials-the-future/): Imagine a cancer patient living in a remote area, struggling with the logistics of participating in a potentially life-altering clinical trial. Decentralized clinical trials (DCTs) offer a solution. Using technology to bring study visits, medication delivery, and monitoring directly to the patient, DCTs break down these barriers, transforming access and hope. To enhance the patient experience and maintain ongoing studies, biopharmaceutical companies and contract research organizations are embracing decentralized clinical trials (DCTs). It is already clear that life science enterprises benefit from DCTs' virtual approach. This translates to significant advantages within the clinical trial landscape, including easier patient and site participation, lowered costs, and streamlined data integration.

## Pages
- [Real World Evidence Studies](https://maxisclinical.com/services/real-world-evidence/real-world-evidence-studies/): Maxis Clinical's Real World Evidence (RWE) Studies services leverages multi-sourced data collection model with advanced analytics tools to provide valuable insights beyond traditional clinical studies, better equipping decision-makers along this product lifecycle journey.
- [Our Leadership Team](https://maxisclinical.com/about-maxis-clinical/our-leadership-team/): Meet the Leadership Team at Maxis Clinical Sciences A unique blend of industry veterans and innovators, is committed to fostering growth and driving innovation globally. Explore their journeys and the opportunities to collaborate or join our team. A Team Steeped in Experience and Diversity Anchored by a diverse group of seasoned professionals and innovators, the leadership team at Maxis Clinical Sciences serves as the foundation for the company's continued success. This team functions as the guiding force, steering the organization toward a future of innovation and excellence in the healthcare and life sciences sector. Divya Reddy Founder and President​ Divya Reddy, the Founder and President of Maxis Group, is a leader known for her innovative spirit and strong leadership. With over 20 years of experience in the Life Sciences & Healthcare sector, Divya has been pivotal to the company's success. Her forward-thinking approach has driven technological product innovations and created new business opportunities. She oversees company's strategies, client relations, and M&A initiatives, ensuring the commercial viability of new business ventures. Divya holds a Master’s degree in Information Technology, which reflects her deep understanding of the intersection between healthcare and technology. Linkedin Highlights Over 20 years in the Life Sciences & Healthcare sector Spearheaded numerous technology product innovations Master’s degree in Information Technology Key Areas of Expertise Strategic Leadership Technology Product Innovations Client Relations & Business Development M&A Initiatives Arati Kapileshwari Head, Business Operations, Clinical Services Arati Kapileshwari has been a key member of Maxis Group for over ten years. With extensive experience in business operations and strategic consulting, she has played a major role in the company's growth. Arati excels at finding top talent and maintaining strong client relationships, which have contributed to the company's success. In her current role, she is responsible for providing business solutions and placing exceptional talent in the Life Sciences sector. Linkedin Harbrinder (Harry) Ghumman Chief People Officer Harry Singh leads Talent Acquisition at Maxis Clinical Sciences and has over 15 years of experience. He has worked with clients in various industries, including Pharma and Healthcare. Harry's deep understanding of business needs and his excellent client and people management skills have helped him create effective recruitment solutions. Known for his precise execution of recruitment processes, Harry is the key person for critical talent acquisition in the Life Sciences sector at Maxis Clinical Sciences. Linkedin Dr. Kavita Lamror Partner, RWE and Digital Transformation Dr. Kavita Lamror is a key figure at Maxis Clinical Sciences. She leads projects that use real-world evidence and digital tools to improve patient health. She earned her Master's in Public Health from Johns Hopkins Bloomberg School of Public Health and has worked in academia, pharmaceuticals, and medical devices. Dr. Lamror uses her expertise in data analysis and evidence-based approaches to enhance patient outcomes. Before joining Maxis, she led global studies on cardiovascular and central nervous system (CNS) products at major pharmaceutical companies. Her leadership has been key in developing custom real-world evidence products and turning these functions into profitable areas for the company. Linkedin Romit Bhalla Director, Business Development - India​ Romit Bhalla is the Director of Business Development for the Indian market at Maxis Clinical Sciences. With over 14 years of experience in HR, staffing, consulting, data cloud solutions, and MICE sectors, Romit is skilled at understanding clients' unique needs and providing tailored solutions. He is responsible for Executive Search, Managed Services, Digital Transformation, FSP Solutions, Strategic Consulting, and Organic growth strategy projects in India. Linkedin Shrikant Ghaytadak HR Leader​ Shrikant Ghaytadak is an HR leader at Maxis Clinical Sciences. With extensive experience in HR and Organizational Development, he has been a key contributor to the company. Shrikant has played a significant role in shaping the company's HR talent model and People Capability framework. He excels in modernizing HR through digital methods, aligning HR strategies with the company's goals, and fostering a culture that reflects the organization's values.​ Linkedin Sristi Shrestha Finance Sristi Shrestha is a Senior Finance Executive at Maxis Clinical Sciences. With 15 years of experience, she oversees the company's financial operations. Sristi has created efficient and cost-effective global financial processes. Her strategic leadership has guided the implementation of various financial initiatives, from top-level strategy development to process improvement directives. Sristi’s work ensures compliance and strong internal controls, making her an important part of the company. Linkedin Careers at MCS Join us in our mission to transform the healthcare landscape. Be a part of a team that is dedicated to advancing research and improving patient outcomes through innovative solutions. Join Us Connect with Us Follow us on our social media platforms to stay updated on our endeavors and join us in our initiatives to transform the healthcare industry Linkedin Facebook Twitter Instagram Youtube Partner with Maxis Clinical Sciences Drive Innovation in Life Sciences and Healthcare Connect With Us
- [HEOR and Epidemiology](https://maxisclinical.com/services/real-world-evidence/heor-and-epidemiology/): We continuously explore and adopt the latest modeling techniques and data analytics tools to provide cutting-edge solutions in HEOR and epidemiology.
- [Use Cases](https://maxisclinical.com/insights/use-cases/): Insights / Use Cases
- [Media](https://maxisclinical.com/insights/media/): Insights / Media
- [White Paper](https://maxisclinical.com/insights/white-papers/): Insights / White Papers
- [Fact sheet](https://maxisclinical.com/insights/fact-sheet/): Fact Sheets
- [Presentation](https://maxisclinical.com/insights/presentation/): Insights / Presentation
- [Brochure](https://maxisclinical.com/insights/brochure/): Insights / Brochure
- [Press Releases](https://maxisclinical.com/insights/press-releases/): Insights / Press Releases
- [Case Studies](https://maxisclinical.com/insights/case-studies/): Insights / Case Studies
- [Functional Service Provider](https://maxisclinical.com/services/functional-service-provider/): Providing tailored solutions to enhance your clinical development potential, the Functional Service Provider (FSP) framework at Maxis Clinical Sciences elevates clinical development by offering an adaptable blend of functional acumen, resource optimization, and tech-driven methodologies to amplify your worldwide initiatives.
- [News and Events](https://maxisclinical.com/insights/news-and-events/): Insights / News and Events
- [Make an appointment](https://maxisclinical.com/make-an-appointment/): Make an appointment Please share your challenge with us; we are ready to collaborate with you on your clinical trials, real-world evidence, FSP and digital health projects to meet today's healthcare challenges with support that is as informed as it is innovative. Write to us at info@maxisclinical.com Contact us
- [About Us](https://maxisclinical.com/about-maxis-clinical/): Maxis Clinical Science Incorporation
- [Blogs](https://maxisclinical.com/insights/blogs/): Insights / Blogs Artificial Intelligence Clinical Biometrics Clinical Research Clinical Trials All
- [Home](https://maxisclinical.com/): An interview with Dr Kavita Lamror, Partner, RWE & Digital Transformation, Maxis CLINICAL SCIEnces
- [Insights](https://maxisclinical.com/insights/): No more posts to show
- [Careers](https://maxisclinical.com/careers/): Join Maxis Clinical Sciences and be part of a community where careers are committed not just to upholding standards, but enhancing them.
- [FAQ](https://maxisclinical.com/faqs/): Real World Evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real World Data (RWD). It provides insights into how a product performs in real-world settings, outside of controlled clinical trials, offering a comprehensive view of effectiveness and safety among diverse patient populations.
- [Contact](https://maxisclinical.com/contact/): Innovative therapeutic development has its challenges. Maxis Clinical Sciences has assembled a top-notch team of experts familiar with these challenges.
- [Strategic Consulting](https://maxisclinical.com/strategic-consulting/): Strategies for compliance within the regulatory landscape.
- [Life Sciences Workforce Solutions](https://maxisclinical.com/services/life-sciences-workforce/): Our strategy is built on a deep understanding of the entire pharmaceutical process, guaranteeing that our partners are equipped with the necessary expertise and personnel to succeed.
- [Digital Health Solutions](https://maxisclinical.com/services/digital-health/): MCS offers a full spectrum of digital health solutions to Life Sciences and MedTech companies, designed to empower patients and enrich their healthcare experience.
- [Digital Health Approach](https://maxisclinical.com/services/digital-health/approach/): MCS utilizes market insights and stakeholder research to shape our digital health solutions. We begin by identifying patient needs and desired outcomes, ensuring our offerings are not only competitive but also adhere to the highest standards of care
- [Clinical Biometric Services](https://maxisclinical.com/services/clinical-biometrics/): Our Clinical Biometrics services portfolio is used by Pharmaceutical, Biopharmaceutical, Biotechnology and Medical Device Companies, Clinical Research Organizations, Healthcare Providers.
- [Revenue Management Services](https://maxisclinical.com/services/real-world-evidence/revenue-management/): Ensuring all revenue management practices adhere to industry regulations and standards.
- [Market Access Services](https://maxisclinical.com/services/real-world-evidence/market-access/): We employ innovative digital strategies and engaging content to enhance market access pathways.
- [Advisory Services](https://maxisclinical.com/services/real-world-evidence/advisory/): We provide end-to-end support, encompassing product conception, new indications, and optimized delivery through healthcare distribution channels.
- [Digital Transformation Solutions](https://maxisclinical.com/services/real-world-evidence/digital-transformation/): We manage RWD transformation using FAIR principles, ensuring data is accurately ingested, converted, cleansed, and formatted.
- [Real World Evidence Solutions](https://maxisclinical.com/services/real-world-evidence/): We believe that the true power of Real World Evidence (RWE) lies in its ability to drive health care innovation and improve patient outcomes.

## Brochures
- [Clinical Function as a Service](https://maxisclinical.com/insights/brochure/clinical-function-as-a-service/)

## Case Study
- [Hybrid FSP for Oncology Research](https://maxisclinical.com/insights/case-study/hybrid-fsp-for-oncology-research/)
- [Advanced Analytics for Rare Disease Research](https://maxisclinical.com/insights/case-study/advanced-analytics-for-rare-disease-research/)
- [Faster Clinical Development with Tech-Enabled FSP Solutions](https://maxisclinical.com/insights/case-study/faster-clinical-development-with-tech-enabled-fsp-solutions/)
- [FSP Strategy to optimize Clinical Trial success](https://maxisclinical.com/insights/case-study/fsp-strategy-to-optimise-clinical-trial-success/)
- [OMOP Model for Clinical Decisions](https://maxisclinical.com/insights/case-study/omop-model-for-clinical-decisions/)
- [Novel Predictive Biomarker Assessment](https://maxisclinical.com/insights/case-study/novel-predictive-biomarker-assessment/)
- [Boosted Clinical Efficiency With FSP](https://maxisclinical.com/insights/case-study/boosted-clinical-efficiency-with-fsp/)
- [Streamlined Biometrics With FSP For Clinical Trials](https://maxisclinical.com/insights/case-study/streamlined-biometrics-with-fsp/)

## Fact Sheet
- [Real World Evidence (RWE) Solutions – One Pager](https://maxisclinical.com/insights/fact-sheet/rwe-solutions/)
- [Maxis Clinical Sciences Overview – One Pager](https://maxisclinical.com/insights/fact-sheet/mcs-overview/)
- [Clinical Biometrics Services – One Pager](https://maxisclinical.com/insights/fact-sheet/clinical-biometrics-services/)
- [Functional Service Provider (FSP) Solutions – One Pager](https://maxisclinical.com/insights/fact-sheet/fsp-solutions/)
- [Maxis Clinical Sciences’ Functional Service Provider (FSP) Models](https://maxisclinical.com/insights/fact-sheet/functional-service-provider-models/)
- [Maxis Clinical Sciences FSP Solutions](https://maxisclinical.com/insights/fact-sheet/maxis-clinical-sciences-fsp-solutions/)

## Openings
- [Senior Multimedia Designer](https://maxisclinical.com/openings/senior-multimedia-designer/)
- [Lead Statistical Programmer](https://maxisclinical.com/openings/lead-statistical-programmer/)
- [Principal Artificial Intelligence Architect](https://maxisclinical.com/openings/principal-artificial-intelligence-architect/)

## Use Case
- [Leveraging Synthetic Data for Real-World Evidence (RWE) in End-Stage Renal Disease (ESRD)](https://maxisclinical.com/insights/use-case/leveraging-synthetic-data-for-rwe-in-esrd/)
- [Privacy-Compliant Clinical Trial Tokenisation for RWE Integration](https://maxisclinical.com/insights/use-case/privacy-compliant-clinical-trial-tokenization-for-rwe-integration/)
- [Health Economic Model for Metastatic Breast Cancer with Partial Survival States Using RWE](https://maxisclinical.com/insights/use-case/health-economic-modeling-metastatic-breast-cancer-oncology/)
- [Adaptive Designs for Clinical Trials to Reduce Time to Market with an RWE Approach](https://maxisclinical.com/insights/use-case/adaptive-designs-for-clinical-trials-rwe-approach/)
- [Building Regulatory-Grade Synthetic Control Arms / External Control Arms with Real World Data](https://maxisclinical.com/insights/use-case/building-regulatory-grade-synthetic-control-arms-with-real-world-data-evidence-rwd-rwe/)
- [Label Expansion of a Diabetes Medication using Observational Cohort Study with RWD / RWE](https://maxisclinical.com/insights/use-case/label-expansion-of-a-diabetes-medication-using-observational-cohort-study-with-rwd-rwe/)

## White Paper
- [Evolving Sponsor-CRO Collaborations Through Decentralized and Hybrid Trials](https://maxisclinical.com/insights/white-paper/evolving-sponsor-cro-collaborations-through-decentralized-and-hybrid-trials/): Opportunities Of UsingGenerative ArtificialIntelligence
- [How Will Embedded FSP Partnerships Change Sponsor-Vendor Collaboration in Clinical Trials?](https://maxisclinical.com/insights/white-paper/how-will-embedded-fsp-partnerships-change-sponsor-vendor-collaboration-in-clinical-trials/): Opportunities Of UsingGenerative ArtificialIntelligence
- [Guidance On GenAI Adoption For Pharma Leaders](https://maxisclinical.com/insights/white-paper/guidance-on-genai-adoption-for-pharma-leaders/): Opportunities Of UsingGenerative ArtificialIntelligence
- [Opportunities Of Using Generative Artificial Intelligence](https://maxisclinical.com/insights/white-paper/opportunities-of-using-generative-artificial-intelligence/): Opportunities Of UsingGenerative ArtificialIntelligence
- [Generating Synthetic Medical Data: A Comprehensive Approach](https://maxisclinical.com/insights/white-paper/generating-synthetic-medical-data-a-comprehensive-approach/)
- [Use of AI and ML for Improving the Quality of RWD](https://maxisclinical.com/insights/white-paper/use-of-aiml-for-improving-the-quality-of-rwd/)